Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV; HIV Infections
MeSH terms: HIV Infections
Intervention: Stribild; Atripla
Intervention description: Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS); Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
Intervention MeSH terms: Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 71.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: HIV; HIV-1; Antiretroviral Treatment-Naive; treatment naive

Summary:

      The objective of this double-blinded, multicenter, randomized, active-controlled study is to
      evaluate the safety and efficacy of Stribild, a single-tablet regimen (STR) containing fixed
      doses of elvitegravir (EVG)/GS-9350 (cobicistat; COBI)/emtricitabine (FTC)/tenofovir
      disoproxil fumarate (TDF) versus efavirenz (EFV)/FTC/TDF (Atripla) in HIV-1 infected,
      antiretroviral treatment-naive adult participants. Stribild offers an alternative STR for
      patients who are not candidates for non-nucleoside reverse transcriptor (NNRTI)-based STRs.

      Participants will be randomized in a 2:1 ratio to receive Stribild or Atripla. Randomization
      will be stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) at
      screening. After Week 48, participants will continue to take their blinded study drug and
      attend visits every 12 weeks until treatment assignments are unblinded (Week 60), at which
      point all participants will attend an Unblinding Visit and be given the option to participate
      in an open-label rollover extension (the extension is scheduled to be open until Stribild
      becomes commercially available, or until Gilead Sciences elects to terminate the study).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Plasma HIV-1 RNA levels ≥ 5,000 copies/mL

          -  No prior use of any approved or experimental anti-HIV drug

          -  Normal electrocardiogram (ECG)

          -  Adequate renal function: estimated glomerular filtration rate ≥ 80 mL/min according to
             the Cockcroft-Gault formula

          -  Hepatic transaminases ≤ 2.5 x upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

          -  Adequate hematologic function

          -  Cluster determinant 4 (CD4) cell count > 50 cells/µL

          -  Serum amylase ≤ 1.5 x ULN

          -  Normal thyroid-stimulating hormone

          -  Negative serum pregnancy test (for females of childbearing potential only)

          -  Males and females of childbearing potential must agree to utilize highly effective
             contraception methods from screening throughout the duration of study treatment and
             for 12 weeks following the last dose of study drugs

          -  Life expectancy ≥ 1 year

          -  Ability to understand and sign a written informed consent form

        Exclusion Criteria:

          -  New acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the
             30 days prior to screening

          -  Documented drug resistance to nucleoside reverse transcriptase inhibitors or
             nonnucleoside reverse transcriptase inhibitors or primary protease inhibitor
             resistance mutation(s)

          -  Hepatitis B surface antigen positive

          -  Hepatitis C antibody positive

          -  Participants experiencing cirrhosis

          -  Participants experiencing ascites

          -  Participants experiencing encephalopathy

          -  Females who are breastfeeding

          -  Positive serum pregnancy test (for females of childbearing potential)

          -  Vaccinated within 90 days of study dosing

          -  History or family history of Long QT Syndrome or family history of sudden cardiac
             death or unexplained death in an otherwise healthy individual under the age of 30

          -  Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac
             conduction abnormalities

          -  Prolonged QTcF interval at screening

          -  PR interval ≥ 200 msec or ≤ 120 msec on ECG at screening

          -  QRS ≥ 120 msec on ECG at screening

          -  Implanted defibrillator or pacemaker

          -  Participants receiving ongoing therapy with any disallowed medications

          -  Current alcohol or substance use judged to potentially interfere with participant
             study compliance

          -  History of or ongoing malignancy (including untreated carcinoma in situ) other than
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
             squamous carcinoma

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to baseline

          -  Participation in any other clinical trial without prior approval

          -  Medications contraindicated for use with EFV, EVG, COBI, FTC, or TDF

          -  Any known allergies to the excipients of Atripla or Stribild tablets

          -  Any other clinical condition or prior therapy that would make the participant
             unsuitable for the study or unable to comply with the dosing requirements